The administration of growth factors as a support intervention such as granulocyte colony-stimulating factors (G-CSF) was allowed in two studies; however, it was not included in the standard treatment regimen.[30, 35] When the use of G-CSFs was recorded as a primary prophylaxis for neutropenia management, it was reported that 32% of patients treated with chemotherapy (n = 137) received some type of G-CSF, and the reactive G-CSFs were the most commonly used type (27%).[42]. This evidence concerns the gene CSF3 and Decreased total neutrophil count.